Agalsidase beta

Drug Profile

Agalsidase beta

Alternative Names: Fabrazyme; Recombinant human α-galactosidase A - Sanofi Genzyme

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Canada; Genzyme Corporation
  • Developer Genzyme Canada; Icahn School of Medicine at Mount Sinai; Sanofi Genzyme
  • Class Galactosidases; Glycoproteins; Isoenzymes
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 17 Aug 2017 Discontinued - Phase-III for Fabry's disease (Early-stage disease, In adolescents, In children, Treatment-naive) in Norway, Netherlands, Canada, Brazil, Argentina, Poland, United Kingdom, Czech Republic, France and USA (IV), because not listed on Sanofi Genzyme pipeline, August 2017
  • 03 Mar 2015 Launched for Fabry's disease in Brazil, Chile, Argentina, Mexico, Malaysia, Turkey, Russia, Switzerland, Hong Kong and India (IV) prior to March 2015
  • 04 Dec 2014 Genzyme completes enrolment in the phase IIIb FILED trial for Fabry's disease (Early-stage disease, In adolescents, In children, Treatment-naive) in USA, Canada, Argentina, Brazil, United Kingdom, Netherlands, Poland, France, Czech Republic and Norway (NCT00701415)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top